Florian Eichler is a Neurology physician affiliated with Massachusetts General Hospital. OpenAlex indexes 9 publications with 249 citations (h-index 4); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
55 Fruit St
Yaw 6b
Boston, MA 02114
Telephone
617-726-6093Registry record last updated 20 Dec 2012.
Clinical trials
- Single Participant Study of an Experimental ASO Treatment for TUBB4A-related Leukodystrophy
Sponsor: Massachusetts General Hospital
- Treating Leg Symptoms in Women With X-linked Adrenoleukodystrophy
Sponsor: Massachusetts General Hospital
- A Natural History of Late Onset Tay-Sachs Disease
Sponsor: Massachusetts General Hospital
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
6 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- ACADIA Pharmaceuticals IncProgram year20253 payments
- SANOFI US SERVICES INC.Program year20252 payments
- Mirum Pharmaceuticals, Inc.Program year20252 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2020)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
62.5%Nonergot Dopamine Agonist62.5%Pramipexole Dihydrochloride100%Part D<11 patientsMetabolism & gastrointestinal
37.5%Bile Acid37.5%Chenodal100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
5 NIH research awards on record, funded 2006–2016 per NIH RePORTER. The latest:
- Safety, Tolerability and Biological Activity of L-serine in HSAN1.
Massachusetts General Hospital
FY2016$102,646R01NS082331
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Neuroradiological patterns and prognostic implications in type I Alexander disease
Molecular Genetics and Metabolism
2026 - Clinically Important Endpoints in Individuals With Leukodystrophy: A Multisite Study
Annals of the Child Neurology Society
2025
Similar KOLs
Other experts from the same institution or the same specialty.
James Januzzi, MD
Massachusetts General Hospital
Maurizio Fava, MD
Massachusetts General Hospital
Steven Greenberg, MD
Massachusetts General Hospital
David Scadden, MD
Massachusetts General Hospital
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”